Emergence of drug resistance in patients with tuberculosis cared for by the Indian health-care system: a dynamic modelling study

详细信息    查看全文

• 作者：Stephanie Law ; MSc^a ; ^b ; Amy S Piatek ; MSc^c ; Cheri Vincent ; MSPH^c ; Olivia Oxlade ; PhD^a ; ^b ; ^&dagger ; ; Prof Dick Menzies ; MD^a ; ^b ; ^&dagger ; ; ^{dick.menzies@mcgill.ca}
• 刊名：The Lancet Public Health
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：2
• 期：1
• 页码：e47-e55
• 全文大小：103 K
• 卷排序：2

文摘

India has the highest number of patients with tuberculosis and multidrug-resistant tuberculosis in the world. We used a transmission model to project the emergence of drug resistance in India due to incorrect tuberculosis management practices in multiple sectors, including public and private providers, chemists, and non-allopathic practitioners.MethodsWe constructed a dynamic Markov model to represent India's tuberculosis epidemic, including a probabilistic framework reflecting complex treatment-seeking pathways. Underlying drug resistance and the acquisition of drug resistance during treatment were included. India-specific epidemiological data, including tuberculosis management practices, were obtained from published literature. Outcomes, which included annual risk of infection, incidence of new disease, prevalence of untreated tuberculosis, and tuberculosis-related mortality, were stratified by underlying drug resistance, as well as by health sector to understand how each sector contributes to the emergence of drug resistance.FindingsIf tuberculosis management practices across sectors in India remain unchanged over the next 20 years, we estimated a 47% increase in the incidence of isoniazid resistance, a 152% increase in multidrug-resistant tuberculosis incidence, a 242% increase in prevalent untreated multidrug-resistant tuberculosis, and a 275% increase in the risk of multidrug-resistant tuberculosis infection. By 2032, an estimated 85% of multidrug-resistant tuberculosis will be primary multidrug-resistant tuberculosis compared with only 15% in 2012. The public sector contributed 87% of acquired multidrug-resistant tuberculosis, related to irregular adherence; the remainder came from the private sector, related to treatment non-completion. Chemists and non-allopathic practitioners do not treat with rifampicin, but because of the high rates of inappropriate isoniazid-containing regimens, and treatment non-adherence, this would generate isoniazid resistance.InterpretationWe predict a gradual transformation from the current epidemic of drug-susceptible tuberculosis to a drug-resistant epidemic. Evidence-based strategies to improve provider practices and patient adherence across health sectors are urgently needed to prevent this.FundingUnited States Agency for International Development and the Canadian Institutes for Health Research.